Rheumatoid Arthritis
Conditions
Keywords
Rheumatoid arthritis, Regulatory B cells, JAK/STAT inhibitors
Brief summary
This study will investigate whether inhibitors of the JAK / STAT signaling pathway can increase anti-inflammatory functions of B cells in patients with RA using in vitro and in vivo experiments.
Detailed description
This study will first analyze the effect of inhibitors of the JAK / STAT pathway in vitro on B-cell phenotypes and functions in 30 RA patients and 30 patients with osteoarthritis. It will also study the phenotypes and functions of B cells in RA patients for whom JAK / STAT inhibitor treatment has been prescribed by the patient's usual rheumatologist. The analysis will be done before the start of treatment and 3 months later. The phenotypes of B-cells will be assessed by flow cytometry with intra- and extra-cellular stainings. The functions of B cells will be assessed by their ability to differenciate naïve T cells in coculture.
Interventions
OTHERBlood sample analysis of patients treated as standard care
Blood sample to analyse percentage of blood cells (regulatory B cells et T cells)
Sponsors
Centre National de la Recherche Scientifique, France
Pfizer
University Hospital, Montpellier
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* General criteria * Patient, of 18 and more years old * Subject affiliated to a social security system * Subject not being in period of exclusion with regard to another protocol * Absence of pregnancy in the inclusion (date of the last period, use of a contraceptive method, ß -HCG impulsive person in case of doubt) * Informed consent * Criteria of inclusion of the group rheumatoid arthritis (in vitro studies): * Rheumatoid arthritis, corresponding to the the classification ACR / EULAR 2010 criteria * Criteria of inclusion of the group arthritis (in vitro studies): * Spinal degenerative osteoarthritis or degenerative osteoarthritis of the members, according to the clinical and radiological elements. * Criteria of inclusion of the group rheumatoid arthritis, longitudinal study at the patients treated by JAK / STAT inhibitors : * Rheumatoid Polyarthritis, corresponding to the classification ACR / EULAR 2010 criteria * Patient to whom a treatment by inhibitor of the way JAK / STAT was proposed in current care of rheumatoid arthritis.
Exclusion criteria
* General criteria * Corticosteroid therapy superior to 10 mg / j * Drip of corticoids in the previous month * Pregnant or breast-feeding Patients * Patient under protection(saving) of justice * Under guardianship Patient or guardianship * Current Infection * Criteria of non-inclusion of the group rheumatoid polyarthritis ( in vitro studies): * Treatment by immunomodulateur or biotherapics (anti-TNF alpha, tocilizumab, abatacept or rituximab) in the previous year * Criteria of non-inclusion of the group arthritis ( in vitro studies): * History of autoimmune disease or néoplasie * Treatment by immunomodulateur or biotherapics (anti-TNF alpha, tocilizumab, abatacept or rituximab) * Criteria of non-inclusion of the group rheumatoid arthritis, longitudinal study at the patients treated by JAK / STAT inhibitors : Treatment by rituximab in the previous year
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of regulatory B cells induced by JAKi in vitro | 4 months | IL-10+ CD19+ cells after in vitro exposure of JAKi |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of regulatory T cells induced by JAKi treated B cells in vitro | 4 months | CD25hiCD126lo/-CD4+ after 3 days of coculture with JAKi pretreated B cells |
| Percentage of Th1 induced by JAKi treated B cells in vitro | 4 months | Interferon gamma+CD4+ after 3 days of coculture with JAKi pretreated B cells |
Countries
France
Outcome results
None listed